v3.25.4
Consolidated Statements of Changes in Series A Preferred Stock and Stockholders' Equity - USD ($)
$ in Thousands
Common Stock [Member]
Additional Paid-In Capital [Member]
Accumulated Deficit [Member]
Total
Series A Preferred Stock [Member]
Balance at Dec. 31, 2023         $ 0
Balance (in shares) at Dec. 31, 2023         0
Increase (Decrease) in Temporary Equity [Roll Forward]          
Issuance of common stock and Series A preferred stock to former private Opus Genetics Inc. stockholders and effect of asset acquisition.         $ 18,843
Issuance of common stock and Series A preferred stock to former private Opus Genetics Inc. stockholders and effect of asset acquisition. (in shares)         14,145.374
Balance at Dec. 31, 2024       $ 18,843 $ 18,843
Balance (in shares) at Dec. 31, 2024         14,145.374
Balance at Dec. 31, 2023 $ 2 $ 131,370 $ (81,466) 49,906  
Balance (in shares) at Dec. 31, 2023 23,977,491        
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of common stock and Series A preferred stock to former private Opus Genetics Inc. stockholders and effect of asset acquisition. $ 1 6,964 0 6,965  
Issuance of common stock and Series A preferred stock to former private Opus Genetics Inc. stockholders and effect of asset acquisition. (in shares) 5,237,063        
Issuance of common stock in connection with the at-the-market program and purchase agreement $ 0 4,497 0 4,497  
Issuance of common stock in connection with the at-the-market program and purchase agreement (in shares) 2,008,522        
Issuance costs $ 0 (395) 0 (395)  
Stock-based compensation $ 0 3,362 0 3,362  
Stock-based compensation (in shares) 395,396        
Share repurchases for the payment of employee taxes $ 0 (79) 0 (79)  
Share repurchases for the payment of employee taxes (in shares) (43,815)        
Net and comprehensive loss $ 0 0 (57,532) (57,532)  
Balance at Dec. 31, 2024 $ 3 145,719 (138,998) 6,724  
Balance (in shares) at Dec. 31, 2024 31,574,657        
Increase (Decrease) in Temporary Equity [Roll Forward]          
Conversion of preferred stock         $ (18,843)
Conversion of preferred stock (in shares)         (14,145.374)
Balance at Dec. 31, 2025       0 $ 0
Balance (in shares) at Dec. 31, 2025         0
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Conversion of preferred stock $ 1 18,842 0 18,843  
Conversion of preferred stock (in shares) 14,145,374        
Issuance of common stock and pre-funded warrants in connection with the March 2025 offering and private placement $ 1 5,979 0 5,980  
Issuance of common stock and pre-funded warrants in connection with the March 2025 offering and private placement (in shares) 13,396,207        
Issuance of common stock and prefunded warrants in connection with registered direct offering $ 1 22,998 0 22,999  
Issuance of common stock and prefunded warrants in connection with registered direct offering (in shares) 3,827,751        
Issuance of common stock in connection with the at-the-market program and purchase agreement $ 1 5,804 0 5,805  
Issuance of common stock in connection with the at-the-market program and purchase agreement (in shares) 5,057,750        
Issuance costs $ 0 (940) 0 (940)  
Stock-based compensation $ 0 3,399 0 3,399  
Stock-based compensation (in shares) 748,977        
Share repurchases for the payment of employee taxes $ 0 (152) 0 (152)  
Share repurchases for the payment of employee taxes (in shares) (86,058)        
Exercise of warrants $ 0 1,872 0 1,872  
Issuance of common stock pursuant to warrants exercises (in shares) 862,684        
Exercise of stock options $ 0 352 0 352  
Exercise of stock options (in shares) 336,759        
Other share issuances $ 0 57 0 57  
Other share issuances (in shares) 30,406        
Net and comprehensive loss $ 0 0 (49,591) (49,591)  
Balance at Dec. 31, 2025 $ 7 $ 203,930 $ (188,589) $ 15,348  
Balance (in shares) at Dec. 31, 2025 69,894,507